Skip to content
Menu name
Menu name
  • FAQ
  • About Us
  • Media
  • Get Involved
  • Shop
  • Our App
  • Surveys
  • Donate
  • Contact
Menu name
Menu name
  • Pain Services Directory
  • About Pain
    • What Is Pain?
    • Common Forms of Pain
    • Who Does Pain Affect?
    • Painful Facts
  • Campaigns and Awareness
    • 2021 International Pain Awareness Month
    • Opioid Reforms
    • Save Paracetamol
    • Chronic Pain in our Defence & Veteran Personnel
  • Real Time Prescription Monitoring
    • SafeScript NSW
    • Canberra Script
  • Health Professionals
    • Education & Training
    • Useful Resources
    • Events for Health Professionals
  • Spinal Cord Stimulation
  • Policy & Research
    • Submissions/Reports
    • National Action Plan
  • Find Support
    • Getting the right care
    • Care in Community
    • Managing Pain and COVID-19
    • Take Home Naloxone


In this issue:

Issue 104
  • A message from the CEO
  • An outgoing message from Painaustralia Chairman, Em Professor Ian Chubb
  • A message from incoming Chairman, Major General Duncan Lewis
  • A big week for pain management in Australia
  • Better Value Healthcare
  • Paracetamol
  • Federal Budget
  • Can you plank for 8 hours and 15 minutes?
  • Naloxone and Stigma
  • Media Issue 104
  • Capital Pain and Rehabilitation Clinic: 20 years serving the act and southeast NSW!

Naloxone and Stigma

Prescribing a medication such as naloxone provides doctors and pharmacists with the opportunity to talk about the risks of opioids with their patients.

In the Medical Journal of Australia, Painaustralia’s CEO Carol Bennett said it is also important for health professionals to address the stigma that can be associated with naloxone.

Ms Bennett said that when doctors and pharmacists talk about naloxone, they needed to be clear about the rationale for the medication, and the patient needed to understand its benefits.

The Australian Government currently has a Take-Home Naloxone Pilot that is running until 30 June 2021. Naloxone is a drug that can temporarily reverse the effects of an opioid overdose or adverse reaction.

The pilot is for:

  • people who are at risk of an opioid overdose or adverse reaction, their carers, friends and family members
  • approved providers such as community pharmacists, dispensing doctors and hospital pharmacists

Painaustralia is keen to hear from consumers who may have had an experience with naloxone.  Please complete oursurvey at https://forms.office.com/r/tCv97TW7xx

Join Painaustralia

If your organisation cares about people in pain and wants to make a difference, please consider becoming a member of Painaustralia.

Our capacity to influence government policy and improve understanding and management of pain is directly related to the strength of our membership network. Your support could make all the difference.
 

Join us

Donate

With one in five Australians living with pain it is likely that someone you know is directly affected. Painaustralia is the national peak body working to improve the quality of life of people living with pain, their families and carers, and to minimise the social and economic burden of pain.

Donations of more than $100 will be acknowledged in the Painaustralia Annual Review, unless you wish to remain anonymous. Note that all donations over $2 are tax deductible.

Donate

 

 

 

PAINAUSTRALIA LIMITED

Mail: PO Box 40, Deakin West, ACT, 2600

© 2020 Painaustralia.  All Rights Reserved.

ABN is 69 147 676 926 
ACN 147 676 926

Tel: 0405 169 766
Email: admin@painaustralia.org.au
Media contact:
0439 958 298

Get in touch



PAINAUSTRALIA PRIVACY POLICY